Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

personalised medicines

- PMLiVE

Pharma fears “lack of focus” on no-deal Brexit preparations

As Brexit is delayed, pharma suggests new measures to avoid no-deal drugs shortages

- PMLiVE

Is Orkambi deal close? Vertex meets again today with NHS England

Campaigners hopes rise after three year wait

- PMLiVE

Is May’s Brexit deal sinking after Speaker’s procedural torpedo?

Life sciences firms must keep planning for no-deal - for now

- PMLiVE

NICE wants to stop saying ‘no’ – but needs pharma’s co-operation

Suggests Orkambi row has undermined confidence in NICE process

- PMLiVE

More Brexit chaos as government suffers more defeats

UK parliament rejects a no-deal Brexit

- PMLiVE

NICE partially clears Darzalex combo in blood cancer

Approved in second-line use under  CDF

- PMLiVE

Brexit deal defeated again, crucial no-deal vote awaits

UK pharma urges no-deal to be ruled out

- PMLiVE

Optimism on Orkambi in England as talks to resume

Scotland's deal puts pressure on NHS England and NICE

- PMLiVE

Shionogi planning HQ move from UK

Brexit understood to be main reason for switch

“Brexit has been a catalyst for UK clinical research… it’s turbocharged change”

The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?

- PMLiVE

Unruffled by ‘outlier’ claims, Vertex CEO upbeat on Orkambi breakthrough

NHS England going public with price makes deal impossible, says Leiden

- PMLiVE

Vertex chief Jeffrey Leiden to weigh in on Orkambi inquiry

Will be joined by chief commercial officer Stuart Arbuckle

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links